A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment - Trial NCT05865171
Access comprehensive clinical trial information for NCT05865171 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
Phase 1
Jun 12, 2023
Dec 01, 2023
Primary Outcome
Maximum Observed Plasma Concentration (Cmax) of IXP,Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP
Summary
The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of
 Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with
 normal renal function.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05865171
Non-Device Trial